Biotechnology deals are off to a strong start in 2018, thanks to the Biotech Showcase 2018 held every year alongside the J.P. Morgan Healthcare Conference. In the first two weeks, 16 transactions were made public. This year, the Showcase registration desk was just getting into full swing on Sunday, January 7, when Celgene Corp. (NASDAQ: CELG) […]
Biotechnology deal activity has climbed steadily over the past five quarters. The sector reached 62 transactions in Q1:17, an increase of 13% over the previous quarter and up 94% year-over-year. The total is 31% of the 203 deals announced in the previous 12 months. M&A in this sector will remain active for years to come, […]
Johnson & Johnson swallowed hard and upped its bid for Swiss biotech Actelion, winning the deal with a $30.2 billion bid.
Deal volume in the Biotechnology sector is poised to surpass last year’s record-setting 160 transactions. With two weeks left in 2016, deal volume has reached 159 transactions. The activity in this sector shows no signs of abating, and will probably carry through the first half of 2017, at least.
Kythera Biopharmaceuticals (NASDAQ: KYTH), a clinical stage biopharma with a penchant for novel prescription products for the aesthetic medical market, entered into separate license agreements with Actellion Pharmceuticals Ltd. and the University of Pennsylvania last month. Actelion is selling the rights to setipiprant, a clinical-stage oral antagonist to the prostaglandin D2 receptor. Under the agreement […]